Prof. Thomas Ritter of NUI Galway has joined “DARTER”- a COST Action CA 17103- Delivery of Antisense RNA Therapeutics. Here, Thomas aims to broaden his research network and to forge new partnerships to explore novel, RNA-based therapies for the treatment of ocular defects and the modulation of corneal transplant rejection.
DARTER has three research objectives- delivery strategies, model systems, safety and toxicology. In addition, there is a capacity-building group for stakeholder communications with the objective to achieve consensus on protocols and assessment of ASO delivery and toxicology and training new researchers within a cooperative research framework. The DARTER COST network includes academics, industrial partners, patient representatives and clinicians and it is open to other interested stakeholders.
COST Actions create spaces where scientists are in the driving seat (bottom-up) and ideas can grow through a flexible and open approach. By enabling researchers from academia, industry and the public and private sector to work together in open networks that transcend borders, COST helps to advance science, stimulates knowledge sharing and pools resources.